Reports record results, raises full-year guidance, accelerates path to positive free cash flow
First quarter highlights
- Total first quarter revenue of $602 million, an increase of 24%, and $598 million of core revenue, an increase of 33%
- Full-year 2023 revenue guidance raised by $110 million at the midpoint
- Expect to turn free cash flow positive during 2023, ahead of previous target of 2024
MADISON, Wis., May 9, 2023 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.